Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls
<p>Pulmonary adenosquamous carcinoma (ASC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with poorly defined molecular characteristics and therapeutic strategies. We present a 63-year-old male patient with stage IVa (cT4N3M1b) lung ASC. Next-generation sequencing (NGS)...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852019003413757952 |
|---|---|
| author | Jun Zhu (84054) |
| author2 | Xin Xun (21603941) Jiayun Liu (12651565) Bin Su (276196) Yi Li (1144) Hong Chen (108084) Meijin Huang (5997851) |
| author2_role | author author author author author author |
| author_facet | Jun Zhu (84054) Xin Xun (21603941) Jiayun Liu (12651565) Bin Su (276196) Yi Li (1144) Hong Chen (108084) Meijin Huang (5997851) |
| author_role | author |
| dc.creator.none.fl_str_mv | Jun Zhu (84054) Xin Xun (21603941) Jiayun Liu (12651565) Bin Su (276196) Yi Li (1144) Hong Chen (108084) Meijin Huang (5997851) |
| dc.date.none.fl_str_mv | 2025-06-26T04:10:03Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1614283.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_Durable_immunotherapeutic_response_in_molecularly_complex_pulmonary_adenosquamous_carcinoma_case_report_and_literature_review_xls/29411294 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology non-small cell lung cancer (NSCLC) lung adenosquamous carcinoma immune checkpoint inhibitors (ICIs) immunotherapy gene mutation |
| dc.title.none.fl_str_mv | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Pulmonary adenosquamous carcinoma (ASC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with poorly defined molecular characteristics and therapeutic strategies. We present a 63-year-old male patient with stage IVa (cT4N3M1b) lung ASC. Next-generation sequencing (NGS) revealed co-occurring mutations in KRAS G12C, BRAF (non-V600E), PIK3CA, and FLT1. Biomarker analysis showed: PD-L1 expression of 18.11% (Tumor Proportion Score, TPS), a tumor mutation burden (TMB) of 3.7 mutations per megabase (mut/Mb), and microsatellite instability (MSI) classified as low (MSI-L) with an instability rate of 35.29%. As first-line treatment, the patient received six cycles of tislelizumab (a PD-1 inhibitor) combined with chemotherapy, followed by tislelizumab maintenance therapy for two years. The patient maintained sustained complete response (CR) with progression-free survival (PFS) reaching 46.5 months, significantly exceeding the typical median PFS of 8-12 months in advanced NSCLC populations. To our knowledge, this presents the first reported case of advanced pulmonary ASC harboring co-occurring driver mutations that demonstrated a remarkable response to immune checkpoint inhibitor (ICI) therapy. Our case highlights the critical role of comprehensive molecular profiling and rational combination strategies in managing rare lung cancer subtypes, establishing a potential treatment paradigm for genomically similar cases.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_6d0697f7eaf56e1f4a3e84ef4e04cb6a |
| identifier_str_mv | 10.3389/fimmu.2025.1614283.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29411294 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xlsJun Zhu (84054)Xin Xun (21603941)Jiayun Liu (12651565)Bin Su (276196)Yi Li (1144)Hong Chen (108084)Meijin Huang (5997851)Genetic Immunologynon-small cell lung cancer (NSCLC)lung adenosquamous carcinomaimmune checkpoint inhibitors (ICIs)immunotherapygene mutation<p>Pulmonary adenosquamous carcinoma (ASC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with poorly defined molecular characteristics and therapeutic strategies. We present a 63-year-old male patient with stage IVa (cT4N3M1b) lung ASC. Next-generation sequencing (NGS) revealed co-occurring mutations in KRAS G12C, BRAF (non-V600E), PIK3CA, and FLT1. Biomarker analysis showed: PD-L1 expression of 18.11% (Tumor Proportion Score, TPS), a tumor mutation burden (TMB) of 3.7 mutations per megabase (mut/Mb), and microsatellite instability (MSI) classified as low (MSI-L) with an instability rate of 35.29%. As first-line treatment, the patient received six cycles of tislelizumab (a PD-1 inhibitor) combined with chemotherapy, followed by tislelizumab maintenance therapy for two years. The patient maintained sustained complete response (CR) with progression-free survival (PFS) reaching 46.5 months, significantly exceeding the typical median PFS of 8-12 months in advanced NSCLC populations. To our knowledge, this presents the first reported case of advanced pulmonary ASC harboring co-occurring driver mutations that demonstrated a remarkable response to immune checkpoint inhibitor (ICI) therapy. Our case highlights the critical role of comprehensive molecular profiling and rational combination strategies in managing rare lung cancer subtypes, establishing a potential treatment paradigm for genomically similar cases.</p>2025-06-26T04:10:03ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1614283.s001https://figshare.com/articles/dataset/Table_1_Durable_immunotherapeutic_response_in_molecularly_complex_pulmonary_adenosquamous_carcinoma_case_report_and_literature_review_xls/29411294CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/294112942025-06-26T04:10:03Z |
| spellingShingle | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls Jun Zhu (84054) Genetic Immunology non-small cell lung cancer (NSCLC) lung adenosquamous carcinoma immune checkpoint inhibitors (ICIs) immunotherapy gene mutation |
| status_str | publishedVersion |
| title | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| title_full | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| title_fullStr | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| title_full_unstemmed | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| title_short | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| title_sort | Table 1_Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review.xls |
| topic | Genetic Immunology non-small cell lung cancer (NSCLC) lung adenosquamous carcinoma immune checkpoint inhibitors (ICIs) immunotherapy gene mutation |